| Gen | % Mutation | Mechanismus | Art der Mutation |
| AR Gen | 62,7% | Androgen - Signaling | Amplification, splice variants, Mutation |
| TP53 | 53,3% | Zellzyklus oder Tumorsuppressor | Mutation, copy loss |
| PTEN | 40,7 % | PI3K–AKT - Regulator | Copy loss, Mutation |
| ETS | 56,7 % | Transkriptions - Regulator | Gen fusions |
| BRCA2 | 13,3 % | DNA - Repair | Copy loss, Mutation |
| KMT2C | 12,7 % | Chromatin modifier | Mutation |
| FOXA1 | 12,0 % | Androgenrezeptor assoziiert | Mutation |
| ZBTB16 | 10,0 % | Androgenrezeptor assoziiert | Copy loss |
| RB1 | 9,3 % | Zellzyklus | Copy loss |
| APC | 8,7 % | Wnt - Pathway | Copy loss, Mutation |
| CHD1 | 8,0 % | Chromatin - Modifier | Copy loss, Mutation |
| SPOP | 8,0 % | Androgen - Signaling | Mutation |
| ATM | 7,3 % | DNA - Repair | Copy loss, Mutation |
AR = Androgen-Rezeptor, nach Daten von (1)
| Gen | % Mutation | RR Metastasen | Bemerkungen |
| BRCA2 | 5,35% | 18,6 | |
| CHEK2 | 1,87 % | 3,1 | |
| ATM | 1,59% | 6,3 | |
| BRCA1 | 0,87 % | 3,9 | |
| GEN1 | 0,46 % | 5,8 | |
| RAD51D | 0,43% | 5,7 | |
| PALB2 | 0,43% | 3,5 |
Nach Daten von (2,3). RR = relatives Risiko von Metastasen
Lymphknoten - Metastasen
Lungen - Metastasen
Nebennieren - Metastase
Quellen
Integrative clinical genomics of advanced prostate cancer.
Cell 2015; 161: 1215-28
2.) Pritchard CC, Morrissey C, Kumar A, et al.:
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer.
Nat Commun 2014; 5: 4988
3.) Pritchard CC, Mateo J, Walsh MF, et al.:
Inherited DNA-repair gene mutations in men with metastatic prostate cancer.
N Engl J Med 2016; 375: 443-53
Teil von
